WHO ICTRP trial
A Phase 2a Multi-centre Randomised Double-Blind Placebo-controlled Study to…
JPRN-jRCT2080221824 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221824 |
|---|---|
| Public title | A Phase 2a Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status |
| Scientific title | A Phase 2a Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line… |
| Primary sponsor | AstraZeneca |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Metastatic, Gastric or Gastro-oesophageal Junction, Cancer |
| Interventions | investigational material(s) Generic name etc : AZD8931 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 40 mg, oral dose twice daily Generic… |
| Registration date | Jun 28, 2012 |
| Secondary IDs | JapicCTI-121867 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: